Back to results
US 2026/0041655 A1Published application
Papd5 inhibitors, pharmaceutical compositions, and methods of treating neurological and cognitive disorders
AssigneeMiralogx LLC
InventorJonnie R. Williams, SR.
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compounds are useful for treating neurological and cognitive disorders such as Alzheimer's disease. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating a neurological disorder, cognitive disorder or a disorder associated with chronic inflammation involves administering the pharmaceutical composition to an individual in need thereof.
Claims18
A compound having a structure of Formula (I):
- wherein R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of an electron pair, H, halogen, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, carboxylate, carboxyl, ester, hydroperoxy, peroxy, ether, hemiacetal, hemiketal, acetal, ketal, orthoester, methylenedioxy, orthocarbonate ester, carboxamide, amine, imine, amide, azide, azo, cyanate, nitrate, nitrile, isonitrile, nitrosooxy, nitro, pyridyl, thiol, sulfide, sulfinyl, sulfonyl, thiocyanate, carbonothioyl, phosphate, and heterocycle;
- optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl;
- wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
- wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl;
- R9 is H or
- wherein each is a single bond or a double bond, with the proviso that within a five-membered ring one or two is a double bond and the remaining are single bonds;
- and wherein X is an electron pair, CH2, SO2 or
- or a pharmaceutically acceptable salt, ester, or ether thereof.
6 more elements
A compound having a structure selected from the group consisting of:
- or a pharmaceutically acceptable salt, ester, or ether thereof.
Dependencies are inferred from the claim text.